Given that defects in BRCA1/2 sensitize breast cancer cells to several DNA-damaging agents [17], we also investigated the correlation between AMH decline during NAC and tumor response to treatment in both gBRCApv and WT patients. This evidence concerns the gene AMH and breast carcinoma.